+2.3 (+10.48%)
Cash Position
-
Monthly Burn
-
Runway
-
locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Small Molecules | Digestive System |
Dated clinical, regulatory & corporate events for Odyssey Therapeutics, Inc.
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OD-07656 Small molecule | Ulcerative Colitis (UC) | Phase 2 | NCT06850727 | 17% | $455M | RECRUITING | 57 | STALLED | B (63) | Nov 1, 2026 | - | May 26, 2026 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OD-001 | ulcerative colitis | Phase 2a | 2026-06-17 | patients completed: 49; clinical remission: 27%; clinical response: 61% Read More | Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More | |
OD-001 | ulcerative colitis | Phase 2a | 2026-06-17 | patients completed: 49; clinical remission: 27%; clinical response: 61% Read More | Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More | |
OD-001 | ulcerative colitis | Phase 2a | 2026-06-17 | patients completed: 49; clinical remission: 27%; clinical response: 61% Read More | Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Evotec SE has partnered with Odyssey Therapeutics to enhance drug discovery for autoimmune and inflammatory diseases. This collaboration will utilize Evotec's AI-enabled platform and advanced screening capabilities to identify new small molecule drug candidates. The goal is to expedite the development of innovative therapies that address significant unmet medical needs.
Read more →Odyssey Therapeutics reported its Q2 2026 financial results, highlighting positive proof-of-concept data for OD-001. The company plans to initiate a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab later this year. With $433.1 million in cash, Odyssey is well-positioned to fund operations into 2028. The company also plans to file a clinical trial application for OD-002 by year-end.
Read more →Odyssey Therapeutics reported positive clinical proof-of-concept data for its oral RIPK2 scaffolding inhibitor, OD-001, in a Phase 2a trial for ulcerative colitis. The company has a strong financial position with $464 million expected to support operations through 2028. Odyssey plans to advance OD-001 into late-stage development and initiate additional trials in the near future.
Read more →Odyssey Therapeutics has appointed Jolie M. Siegel as Executive Vice President and General Counsel. Siegel will oversee legal, compliance, governance, and risk management functions, playing a key role in supporting the company's growth and strategic opportunities. With over two decades of experience in biotechnology and life sciences, her leadership is expected to enhance Odyssey's capabilities in advancing therapies for autoimmune diseases.
Read more →Odyssey Therapeutics has appointed Dennis Dean, Ph.D., as Executive Vice President and Head of Nonclinical Development. Dr. Dean will oversee preclinical research and development, ensuring the progression of drug candidates to clinical trials. His extensive experience in toxicology and pharmacology is expected to enhance the company's capabilities as it advances its portfolio.
Read more →Odyssey Therapeutics has appointed Dr. Nia Tatsis to its Board of Directors. Dr. Tatsis, with over 20 years of experience in regulatory affairs, is expected to contribute significantly to the company's clinical development efforts. Odyssey aims to transform care for autoimmune and inflammatory diseases, and Dr. Tatsis's expertise will support their mission to advance their innovative pipeline.
Read more →Odyssey Therapeutics has successfully closed a $213 million Series D financing round, with participation from existing and new investors. The funds will support the advancement of their clinical and preclinical programs targeting autoimmune diseases. The company aims to transform patient care through innovative therapies and has appointed new board members to enhance its governance.
Read more →Odyssey Therapeutics has appointed Jason Haas as Chief Financial Officer. With over two decades of experience in financial strategy and operations, Haas will play a key role in advancing the company's financial strategy and growth. His previous roles include CFO at Syros Pharmaceuticals and senior positions in investment banking. The company aims to transform care for autoimmune diseases.
Read more →Odyssey Therapeutics and Terray Therapeutics have announced a strategic collaboration to discover and develop small molecule therapies targeting transcription factors. This partnership leverages Odyssey's immunology expertise and Terray's advanced AI platform, tNova. The goal is to create innovative treatments for inflammatory diseases, sharing responsibilities and profits equally.
Read more →Odyssey Therapeutics will present new data on its RIPK2 scaffolding inhibitor, OD-07656, at the ACG Annual Scientific Meeting 2024. The presentation will highlight the compound's anti-inflammatory effects and its potential to work alongside standard therapies for inflammatory bowel disease. CEO Gary D. Glick emphasized the commitment to developing transformative treatments for patients.
Read more →Odyssey Therapeutics has appointed Timothy P. Walbert and Ian F. Smith to its Board of Directors. Both individuals bring extensive experience in the biopharmaceutical industry, with Walbert having led Horizon Therapeutics and Smith having played a key role at Vertex Pharmaceuticals. Their appointments are expected to enhance Odyssey's strategic growth as it advances its pipeline of precision medicines for inflammatory diseases.
Read more →Odyssey Therapeutics has announced the formation of its Scientific Advisory Board, chaired by Dr. Stephen Blacklow. The board consists of leading experts in immunology and therapeutic development, aimed at guiding the company's innovative approaches to treating inflammatory diseases. Odyssey's mission focuses on advancing precision medicines and improving patient outcomes.
Read more →Odyssey Therapeutics has appointed Dr. William Roush as Executive Vice President and Head of Small Molecule Research. Dr. Roush brings a wealth of experience in organic and medicinal chemistry, having led numerous drug discovery programs. His role will involve overseeing the preclinical portfolio and accelerating the development of innovative small molecule medicines for autoimmune and inflammatory diseases.
Read more →Odyssey Therapeutics has announced a strategic collaboration with Janssen Pharmaceutica to enhance the discovery and optimization of small molecule medicines. This partnership will leverage artificial intelligence and machine learning to address challenging therapeutic targets. Odyssey will receive upfront payments and potential royalties as they work together on this initiative.
Read more →Odyssey Therapeutics has successfully closed a $101 million Series C financing round, led by Ascenta Capital, with participation from various investors. This funding will facilitate the advancement of multiple clinical programs and support ongoing discovery efforts. The company aims to bring transformative immunology and oncology medicines to patients, with several candidates expected to enter clinical trials within the next year.
Read more →Odyssey Therapeutics will present data on three immunology programs at the ACR Convergence 2023. The presentations will include novel therapeutic approaches targeting RIPK2, IRAK4, and TNFR2, which are crucial for treating underserved inflammatory and autoimmune diseases. This marks the first public disclosure of these promising therapies aimed at improving patient outcomes.
Read more →